HuGE Literature Finder
Records
1
-
1
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jan 18 (2): 555-67. Kirkwood John M, Bastholt Lars, Robert Caroline, Sosman Jeff, Larkin James, Hersey Peter, Middleton Mark, Cantarini Mireille, Zazulina Victoria, Kemsley Karin, Dummer Reinha |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 28, 2023
- Content source: